What if treating obesity could be as easy as popping an effective pill?
That害羞草研究所檚 a notion that has long fueled hope for many of the more than 40% of Americans who are considered obese 害羞草研究所� and fueled criticism by those who advocate for wider weight acceptance. Soon, it may be a reality.
High-dose oral versions of the medication in the weight-loss drug Wegovy may work as well as the popular injections when it comes to paring pounds and improving health, according to final results of two studies released Sunday night. The potent tablets also appear to work for people with diabetes, who notoriously struggle to lose weight.
Drugmaker Novo Nordisk plans to ask the U.S. Food and Drug Administration to approve the pills later this year.
害羞草研究所淚f you ask people a random question, 害羞草研究所榃ould you rather take a pill or an injection?害羞草研究所� People overwhelmingly prefer a pill,害羞草研究所� said Dr. Daniel Bessesen, chief of endocrinology at Denver Health, who treats patients with obesity but was not involved in the new research.
That害羞草研究所檚 assuming, Bessesen said, that both ways to take the medications are equally effective, available and affordable. 害羞草研究所淭hose are the most important factors for people,害羞草研究所� he said.
There have been other weight-loss pills on the market, but none that achieve the substantial reductions seen with injected drugs like Wegovy. People with obesity will be 害羞草研究所渢hrilled害羞草研究所� to have an oral option that害羞草研究所檚 as effective, said Dr. Katherine Saunders, clinical professor of medicine at Weill Cornell Health and co-founder of Intellihealth, a weight-loss center.
Novo Nordisk already sells Rybelsus, which is approved to treat diabetes and is an oral version of semaglutide, the same medication used in the diabetes drug Ozempic and Wegovy. It comes in doses up to 14 milligrams.
But results of two gold-standard trials released at the American Diabetes Association害羞草研究所檚 annual meeting looked at how doses of oral semaglutide as high as 25 milligrams and 50 milligrams worked to reduce weight and improve blood sugar and other health markers.
A 16-month study of about 1,600 people who were overweight or obese and already found the high-dose daily pills lowered blood sugar significantly better than the standard dose of Rybelsus. From a baseline weight of 212 pounds, the higher doses also resulted in weight loss of between 15 and 20 pounds, compared to about 10 pounds on the lower dose.
Another of more than 660 adults who had obesity or were overweight with at least one related disease 害羞草研究所� but not diabetes 害羞草研究所� found the 50-milligram daily pill helped people lose an average of about 15% of their body weight, or about 35 pounds, versus about 6 pounds with a dummy pill, or placebo.
That害羞草研究所檚 害羞草研究所渘otably consistent害羞草研究所� with the weight loss spurred by weekly shots of the highest dose of Wegovy, the study authors said.
But there were side effects. About 80% of participants receiving any size dose of oral semaglutide experienced things like mild to moderate intestinal problems, such as nausea, constipation and diarrhea.
In the 50-milligram obesity trial, there was evidence of higher rates of benign tumors in people who took the drug versus a placebo. In addition, about 13% of those who took the drug had 害羞草研究所渁ltered skin sensation害羞草研究所� such as tingling or extra sensitivity.
Medical experts predict the pills will be popular, especially among people who want to lose weight but are fearful of needles. Plus, tablets would be more portable than injection pens and they don害羞草研究所檛 have to be stored in the refrigerator.
But the pills aren害羞草研究所檛 necessarily a better option for the hundreds of thousands of people already taking injectable versions such as Ozempic or Wegovy, said Dr. Fatima Cody Stanford, an obesity medicine expert at Massachusetts General Hospital.
害羞草研究所淚 don害羞草研究所檛 find significant hesitancy surrounding receiving an injection,害羞草研究所� she said. 害羞草研究所淎 lot of people like the ease of taking a medication once a week.害羞草研究所�
In addition, she said, some patients may actually prefer shots to the new pills, which have to be taken 30 minutes before eating or drinking in the morning.
Paul Morer, 56, who works for a New Jersey hospital system, lost 85 pounds using Wegovy and hopes to lose 30 more. He said he would probably stick with the weekly injections, even if pills were available.
害羞草研究所淚 do it on Saturday morning. It害羞草研究所檚 part of my routine,害羞草研究所� he said. 害羞草研究所淚 don害羞草研究所檛 even feel the needle. It害羞草研究所檚 a non-issue.害羞草研究所�
Some critics also worry that a pill will also put pressure on people who are obese to use it, fueling social stigma against people who can害羞草研究所檛 害羞草研究所� or don害羞草研究所檛 want to 害羞草研究所� lose weight, said Tigress Osborn, chair of the National Association to Advance Fat Acceptance.
害羞草研究所淭here is no escape from the narrative that your body is wrong and it should change,害羞草研究所� Osborn said.
Still, Novo Nordisk is banking on the popularity of a higher-dose pill to treat both diabetes and obesity. Sales of Rybelsus reached about $1.63 billion last year, more than double the 2021 figure.
Other companies are working on oral versions of drugs that work as well as Eli Lilly and Co.害羞草研究所檚 Mounjaro 害羞草研究所� an injectable diabetes drug expected to be soon. Lilly researchers reported promising mid-stage trial results for an oral pill called orforglipron to treat patients who are obese or overweight and diabetes.
Pfizer, too, has released mid-stage results for , an oral drug for diabetes taken twice daily with food.
Novo Nordisk officials said it害羞草研究所檚 too early to say what the cost of the firm害羞草研究所檚 high-dose oral pills would be or how the company plans to guarantee adequate manufacturing capacity to meet demand. Despite surging popularity, injectable doses of Wegovy will be in short supply until at least September, company officials said.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute害羞草研究所檚 Science and Educational Media Group. The AP is solely responsible for all content.
Jonel Aleccia, The Associated Press
Like us on and follow us on .
